Message Communicating Latest Data on COVID-19 Transmission in Patient's Area

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05621226

Enrollment

520000

Registered

2022-11-17

Start date

2022-11-03

Completion date

2023-02-06

Last updated

2023-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Keywords

COVID-19, behavioral science interventions, vaccination promotion

Brief summary

This experiment is part of a megastudy with a total of ten experimental conditions and a holdout control condition to which patients will be randomly assigned. The focal comparison in this experiment is between a message encouraging vaccination by communicating to patients that they live in an area with significant COVID transmission and a control message telling patients that an updated COVID booster vaccine is waiting for them.

Interventions

BEHAVIORALCOVID Booster text messages

Participants will receive text messages per descriptions listed in the arms.

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

DOUBLE (Caregiver, Outcomes Assessor)

Masking description

As treated participants will receive text messages, there is no scope for blinding. Care providers will not be made aware of subjects' participation in the study, or assigned treatment arms. The study team will only receive data on subjects' assigned arms and outcomes at the end of the study.

Intervention model description

Participants will be randomly assigned to the different arms.

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Exclusion criteria

1. The patient unsubscribed from texts before the send date and time of the patient's SMS/MMS message 2. The patient received a bivalent COVID booster before the send date and time of the patient's SMS/MMS message.

Design outcomes

Primary

Measure	Time frame	Description
Patient uptake of COVID bivalent booster	During the 30 days after receiving the SMS/MMS intervention	Whether patients receive a bivalent COVID booster at the pharmacy in question

Secondary

Measure	Time frame	Description
Patient uptake of COVID bivalent booster	60 days after receiving the SMS/MMS intervention	Whether patients receive a bivalent COVID booster at the pharmacy in question

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026